PL443075A1 - Ryzyko zachorowania na raka u kobiet poniżej 50 roku życia z dziedziczną predyspozycją do raka piersi - Google Patents
Ryzyko zachorowania na raka u kobiet poniżej 50 roku życia z dziedziczną predyspozycją do raka piersiInfo
- Publication number
- PL443075A1 PL443075A1 PL443075A PL44307522A PL443075A1 PL 443075 A1 PL443075 A1 PL 443075A1 PL 443075 A PL443075 A PL 443075A PL 44307522 A PL44307522 A PL 44307522A PL 443075 A1 PL443075 A1 PL 443075A1
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- assessing
- age
- years
- reduced risk
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 108700040618 BRCA1 Genes Proteins 0.000 abstract 1
- 101150072950 BRCA1 gene Proteins 0.000 abstract 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract 1
- 229910052785 arsenic Inorganic materials 0.000 abstract 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 229910052711 selenium Inorganic materials 0.000 abstract 1
- 239000011669 selenium Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Zgłoszenie opisuje sposób oceny zmniejszonego ryzyka zachorowania na raka u pacjentki z dziedziczną predyspozycją do raka piersi, bez mutacji w genie BRCA1 oraz poniżej 50 roku życia. Sposób obejmuje ocenę stężenia arsenu oraz selenu we krwi pacjentki przy jednoczesnej ocenie wartości indeksu ryzyka.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL443075A PL443075A1 (pl) | 2022-12-07 | 2022-12-07 | Ryzyko zachorowania na raka u kobiet poniżej 50 roku życia z dziedziczną predyspozycją do raka piersi |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL443075A PL443075A1 (pl) | 2022-12-07 | 2022-12-07 | Ryzyko zachorowania na raka u kobiet poniżej 50 roku życia z dziedziczną predyspozycją do raka piersi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL443075A1 true PL443075A1 (pl) | 2024-06-10 |
Family
ID=91432155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL443075A PL443075A1 (pl) | 2022-12-07 | 2022-12-07 | Ryzyko zachorowania na raka u kobiet poniżej 50 roku życia z dziedziczną predyspozycją do raka piersi |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL443075A1 (pl) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL425602A1 (pl) * | 2018-05-17 | 2019-01-02 | Read-Gene Spółka Akcyjna | Sposób określenia ryzyka raków u kobiet nie będących nosicielkami mutacji w genie BRCA1 i BRCA2 w zależności od stężeń we krwi arsenu, kadmu, cynku i/lub selenu |
-
2022
- 2022-12-07 PL PL443075A patent/PL443075A1/pl unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL425602A1 (pl) * | 2018-05-17 | 2019-01-02 | Read-Gene Spółka Akcyjna | Sposób określenia ryzyka raków u kobiet nie będących nosicielkami mutacji w genie BRCA1 i BRCA2 w zależności od stężeń we krwi arsenu, kadmu, cynku i/lub selenu |
Non-Patent Citations (1)
| Title |
|---|
| CHEN Y. ET AL: "Cancer Epidemiol Biomarkers Prev. 2007 February; 16(2): 207-213", "A PROSPECTIVE STUDY OF BLOOD SELENIUM LEVELS AND THE RISK OF ARSENIC-RELATED PREMALIGNANT SKIN LESIONS" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kubilus et al. | Steroid-sulfatase deficiency in sex-linked ichthyosis | |
| LEVI et al. | Socioeconomic groups and cancer risk at death in the Swiss Canton of Vaud | |
| Baade et al. | Prognostic survival model for people diagnosed with invasive cutaneous melanoma | |
| CN108288130A (zh) | 基于数据挖掘分析平台的临床护理绩效评价系统及方法 | |
| Paolino et al. | Clinicopathological features, vitamin D serological levels and prognosis in cutaneous melanoma of shield-sites: An update | |
| Liberati et al. | Determinants of physicians’ preferences for alternative treatments in women with early breast cancer | |
| PL443075A1 (pl) | Ryzyko zachorowania na raka u kobiet poniżej 50 roku życia z dziedziczną predyspozycją do raka piersi | |
| Cornelius et al. | Comparison of US oncologist rurality by practice setting and patients served | |
| Hernández-Boluda et al. | Prognostic risk models for transplant decision-making in myelofibrosis | |
| Gurnari et al. | IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria | |
| Ayanlowo et al. | Cutaneous cancers in the Africans: Systematic review | |
| Richards et al. | Determinants of 6-month survival of critically ill patients with an active hematologic malignancy | |
| Naik et al. | The association between glucose-6-phosphate dehydrogenase deficiency and cancer in American Negroes | |
| Smith | A possible biologic role of dreaming | |
| PL425602A1 (pl) | Sposób określenia ryzyka raków u kobiet nie będących nosicielkami mutacji w genie BRCA1 i BRCA2 w zależności od stężeń we krwi arsenu, kadmu, cynku i/lub selenu | |
| Wolska et al. | Comparison of long-term outcomes of breast conservation and reconstruction after mastectomy using BREAST-Q | |
| Smith et al. | Providing more up-to-date estimates of patient survival: a comparison of standard survival analysis with period analysis using life-table methods and proportional hazards models | |
| PL445013A1 (pl) | Dieta ubogoarsenowa a ryzyko raków u kobiet | |
| Morales et al. | Outcomes of hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia: a multicenter Brazilian cohort study | |
| Kondo et al. | Pre-transplant blinatumomab and/or inotuzumab ozogamicin therapy for relapsed/refractory acute lymphoblastic and B/myeloid mixed phenotype acute leukemia in adults | |
| Zahl | A proportional regression model for 20 year survival of colon cancer in Norway | |
| Gore | Classification, Treatment Goals, and Management Principles for Myelodysplasic Syndromes | |
| Rustamzada et al. | Frailty and dependency in kidney transplant candidates | |
| Hong et al. | Influence of killer immunoglobulin-like receptors and somatic mutations on transplant outcomes in acute myeloid leukemia | |
| Gilbert et al. | Clinical features and outcomes of acquired versus baseline TP53 mutations in myeloid neoplasms: A single-center retrospective analysis |